TriSalus Life Sciences, Inc.
TLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $132,773 | $223,635 | $296,972 | $308,750 |
| - Cash | $8,525 | $11,777 | $9,414 | $30,301 |
| + Debt | $23,629 | $1,595 | $1,963 | $544 |
| Enterprise Value | $147,877 | $213,453 | $289,521 | $278,993 |
| Revenue | $29,431 | $18,511 | $12,398 | $8,401 |
| % Growth | 59% | 49.3% | 47.6% | – |
| Gross Profit | $25,328 | $15,906 | $10,140 | $7,208 |
| % Margin | 86.1% | 85.9% | 81.8% | 85.8% |
| EBITDA | -$36,165 | -$58,654 | -$46,763 | -$23,568 |
| % Margin | -122.9% | -316.9% | -377.2% | -280.5% |
| Net Income | -$33,233 | -$59,363 | -$47,187 | -$28,845 |
| % Margin | -112.9% | -320.7% | -380.6% | -343.4% |
| EPS Diluted | -1.25 | -2.23 | -1.59 | -0.92 |
| % Growth | 43.9% | -40.3% | -72.8% | – |
| Operating Cash Flow | -$40,843 | -$50,578 | -$32,313 | -$22,697 |
| Capital Expenditures | -$345 | -$588 | -$786 | -$1,258 |
| Free Cash Flow | -$41,188 | -$51,166 | -$33,099 | -$23,955 |